ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Breast Cancer trials near Cleveland, OH, USA:

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy \[paclitaxel\] and a ...

Active, not recruiting
Breast Cancer Metastatic
Biological: Pelareorep
Drug: Paclitaxel

Phase 2

Oncolytics Biotech

Cleveland, Ohio, United States and 17 other locations

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Cleveland, Ohio, United States and 226 other locations

participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...

Enrolling
Breast Cancer
Locally Advanced Breast Cancer
Drug: Elacestrant Dihydrochloride
Drug: Samuraciclib

Phase 1, Phase 2

Carrick Therapeutics

Cleveland, Ohio, United States and 26 other locations

The purpose of this study is to evaluate the safety and tolerability of talectrectinib as treatment for Stage IV ILC with CDH1 mutation

Begins enrollment in 2 months
Breast Cancer
Metastatic Breast Cancer
Drug: Taletrectinib

Phase 2

Megan Kruse, MD

Cleveland, Ohio, United States and 1 other location

with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...

Active, not recruiting
Breast Cancer
Drug: Vinorelbine
Drug: Eribulin

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 166 other locations

and demonstrate efficacy in patients with advanced triple-negative breast cancer.This study will take place in two parts. Stage 1 w...

Active, not recruiting
Triple-negative Breast Cancer
Biological: Pembrolizumab
Biological: AE37 Peptide vaccine

Phase 2

NuGenerex Immuno-Oncology

Cleveland, Ohio, United States and 5 other locations

versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane....

Active, not recruiting
Breast Cancer
Drug: Trastuzumab deruxtecan (T-DXd)
Drug: Ado-trastuzumab emtansine (T-DM1)

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Cleveland, Ohio, United States and 163 other locations

with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determine...

Enrolling
HER2-negative Breast Cancer
Drug: Weekly Paclitaxel
Drug: Pertuzumab

Phase 2

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Cleveland, Ohio, United States and 42 other locations

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Other: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Cleveland, Ohio, United States and 805 other locations

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy a...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Cleveland, Ohio, United States and 482 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems